• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Search for New 2-18F-FDG PET/CT Imaging Biomarkers in Advanced Ovarian Cancer Patients: Focus on Peritoneal Staging for Guiding Precision Medicine and Management Decisions.

作者信息

Delgado Bolton Roberto C, Calapaquí Terán Adriana K, Pellet Olivier, Ferrero Annamaria, Giammarile Francesco

机构信息

From the Department of Diagnostic Imaging (Radiology) and Nuclear Medicine, University Hospital San Pedro and Centre for Biomedical Research of La Rioja, Logroño, La Rioja.

Department of Pathology, University Hospital Marqués de Valdecilla, Santander, Spain.

出版信息

Clin Nucl Med. 2021 Nov 1;46(11):906-907. doi: 10.1097/RLU.0000000000003784.

DOI:10.1097/RLU.0000000000003784
PMID:34238809
Abstract
摘要

相似文献

1
The Search for New 2-18F-FDG PET/CT Imaging Biomarkers in Advanced Ovarian Cancer Patients: Focus on Peritoneal Staging for Guiding Precision Medicine and Management Decisions.晚期卵巢癌患者新型2-18F-FDG PET/CT成像生物标志物的探索：聚焦于用于指导精准医学和管理决策的腹膜分期
Clin Nucl Med. 2021 Nov 1;46(11):906-907. doi: 10.1097/RLU.0000000000003784.
2
Molecular Imaging and Precision Medicine in Uterine and Ovarian Cancers.子宫癌和卵巢癌的分子成像与精准医学
PET Clin. 2017 Oct;12(4):393-405. doi: 10.1016/j.cpet.2017.05.007. Epub 2017 Jul 19.
3
Imaging biomarkers in ovarian cancer: the role of ¹⁸F-FDG PET/CT.卵巢癌中的影像学生物标志物：¹⁸F-FDG PET/CT的作用
Q J Nucl Med Mol Imaging. 2016 Jun;60(2):93-102. Epub 2016 Feb 9.
4
Use of (18)F-FDG PET/CT in the preoperative evaluation of patients diagnosed with peritoneal carcinomatosis of ovarian origin, candidates to cytoreduction and hipec. A pending issue.（18）F-FDG PET/CT在卵巢源性腹膜癌患者术前评估中的应用，这些患者是细胞减灭术和腹腔内热灌注化疗的候选者。一个悬而未决的问题。
Eur J Radiol. 2016 Oct;85(10):1824-1828. doi: 10.1016/j.ejrad.2016.08.006. Epub 2016 Aug 11.
5
Role of F-fluoro-2-deoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in malignant ovarian germ cell tumors: a single-center experience with long term follow-up.F-氟代-2-脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（18F-FDG PET/CT）在恶性卵巢生殖细胞肿瘤中的作用：一项具有长期随访的单中心经验。
Int J Gynecol Cancer. 2019 Oct;29(8):1298-1303. doi: 10.1136/ijgc-2019-000586. Epub 2019 Jul 30.
6
Clinical impact of pre-treatment FDG-PET/CT staging of primary ovarian, fallopian tube, and peritoneal cancers in women.术前 18F-FDG PET/CT 分期对原发性卵巢癌、输卵管癌和腹膜癌患者的临床影响。
Acta Obstet Gynecol Scand. 2020 Feb;99(2):186-195. doi: 10.1111/aogs.13726. Epub 2019 Sep 25.
7
The value of [18F]FDG PET/CT examination in the detection and differentiation of recurrent ovarian cancer.[18F]FDG PET/CT 检查在复发性卵巢癌的检测和鉴别诊断中的价值。
Nucl Med Rev Cent East Eur. 2023;26(0):98-105. doi: 10.5603/NMR.2023.0013.
8
Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian/fallopian tube/primary peritoneal cancer.正电子发射断层扫描（PET）和磁共振成像（MRI）用于评估晚期上皮性卵巢癌/输卵管癌/原发性腹膜癌的肿瘤可切除性。
Cochrane Database Syst Rev. 2018 Oct 8;10(10):CD012567. doi: 10.1002/14651858.CD012567.pub2.
9
The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer.18F-FDG PET/CT 显像联合 CA125 和 HE4 检测在卵巢癌复发转移诊断中的价值。
Eur Rev Med Pharmacol Sci. 2020 Jul;24(13):7276-7283. doi: 10.26355/eurrev_202007_21882.
10
Impact of positron emission tomography/computed tomography in the management of patients with epithelial ovarian carcinoma after treatment.正电子发射断层扫描/计算机断层扫描对治疗后上皮性卵巢癌患者管理的影响。
Arch Gynecol Obstet. 2011 May;283(5):1121-6. doi: 10.1007/s00404-010-1568-0. Epub 2010 Jun 24.

引用本文的文献

1
PET/CT Volumetric Parameters as Predictors of the Peritoneal Cancer Index in Advanced Ovarian Cancer Patients.PET/CT体积参数作为晚期卵巢癌患者腹膜癌指数的预测指标
Diagnostics (Basel). 2025 Jul 19;15(14):1818. doi: 10.3390/diagnostics15141818.
2
Diagnostic accuracy and clinical value of [68Ga]Ga-FAPI-46 PET/CT for staging patients with ovarian cancer: study protocol for a prospective clinical trial.[68Ga]Ga-FAPI-46 PET/CT 诊断卵巢癌患者分期的准确性和临床价值：一项前瞻性临床试验的研究方案。
BMC Cancer. 2024 Jun 7;24(1):699. doi: 10.1186/s12885-024-12461-w.
3
Survival time prediction in patients with high-grade serous ovarian cancer based on F-FDG PET/CT- derived inter-tumor heterogeneity metrics.
基于 F-FDG PET/CT 衍生的肿瘤间异质性指标预测高级别浆液性卵巢癌患者的生存时间。
BMC Cancer. 2024 Mar 12;24(1):337. doi: 10.1186/s12885-024-12087-y.
4
Ga-PSMA PET/CT-based multivariate model for highly accurate and noninvasive diagnosis of clinically significant prostate cancer in the PSA gray zone.基于 Ga-PSMA PET/CT 的多变量模型，可实现 PSA 灰区中具有临床意义的前列腺癌的高度准确和无创诊断。
Cancer Imaging. 2023 Sep 4;23(1):81. doi: 10.1186/s40644-023-00562-x.
5
VGLL3 expression is associated with macrophage infiltration and predicts poor prognosis in epithelial ovarian cancer.VGLL3表达与巨噬细胞浸润相关，并可预测上皮性卵巢癌的不良预后。
Front Oncol. 2023 Jun 5;13:1152991. doi: 10.3389/fonc.2023.1152991. eCollection 2023.
6
Expression and clinical significance of NCOA5 in epithelial ovarian cancer.NCOA5在上皮性卵巢癌中的表达及临床意义
Front Oncol. 2023 May 1;13:1117033. doi: 10.3389/fonc.2023.1117033. eCollection 2023.
7
Prognostic value of β-Arrestins in combination with glucocorticoid receptor in epithelial ovarian cancer.β-抑制蛋白与糖皮质激素受体联合在上皮性卵巢癌中的预后价值
Front Oncol. 2023 Mar 10;13:1104521. doi: 10.3389/fonc.2023.1104521. eCollection 2023.
8
Meta-analysis of the diagnostic value of F-FDG PET/CT in the recurrence of epithelial ovarian cancer.F-FDG PET/CT对上皮性卵巢癌复发诊断价值的Meta分析。
Front Oncol. 2022 Nov 7;12:1003465. doi: 10.3389/fonc.2022.1003465. eCollection 2022.